HER2-positive metastatic breast cancer: A changing scenario

Mustacchi, Giorgio; Biganzoli, Laura; Pronzato, P.; Montemurro, Filippo; Dambrosio, M.; Minelli, Mauro; Molteni, L.; Scaltriti, Laura

doi:10.1016/j.critrevonc.2015.02.002

Cited by 28 publications

(15 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Breast cancer is the most prevalent type of cancer in women [ 1 ]. Although a multitude of treatment options are available [ 2 – 4 ], approximately one-third of women worldwide diagnosed with breast cancer still die from the disease, largely from metastasis, especially brain metastasis [ 5 – 8 ]. EVs have been hypothesized to have significant roles in breast cancer growth and metastasis and thus have been evaluated as potential avenues of new therapeutic intervention.…”

Section: Introductionmentioning

confidence: 99%

Breast Cancer-Derived Extracellular Vesicles: Characterization and Contribution to the Metastatic Phenotype

Green

Alpaugh

Barsky

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

The study of extracellular vesicles (EVs) in cancer progression is a complex and rapidly evolving field. Whole categories of cellular interactions in cancer which were originally presumed to be due solely to soluble secreted molecules have now evolved to include membrane-enclosed extracellular vesicles (EVs), which include both exosomes and shed microvesicles (MVs), and can contain many of the same molecules as those secreted in soluble form but many different molecules as well. EVs released by cancer cells can transfer mRNA, miRNA, and proteins to different recipient cells within the tumor microenvironment, in both an autocrine and paracrine manner, causing a significant impact on signaling pathways, mRNA transcription, and protein expression. The transfer of EVs to target cells, in turn, supports cancer growth, immunosuppression, and metastasis formation. This review focuses exclusively on breast cancer EVs with an emphasis on breast cancer-derived exosomes, keeping in mind that breast cancer-derived EVs share some common physical properties with EVs of other cancers.

show abstract

Section: Introductionmentioning

confidence: 99%

Breast Cancer-Derived Extracellular Vesicles: Characterization and Contribution to the Metastatic Phenotype

Green

Alpaugh

Barsky

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Nab-paclitaxel in HER2-positive metastatic breast cancer Treatment options and outcomes for HER2-positive (HER2+) MBC have improved significantly over the past decade with the availability of several agents targeting the HER2 pathway, including trastuzumab, lapatinib, pertuzumab, and more recently trastuzumab emtansine [Mustacchi et al 2015]. In early as well as advanced disease, synergy between chemotherapy and HER2-directed therapy has improved PFS and OS, compared with chemotherapy alone [Balduzzi et al 2014].…”

Section: Clinical Development Of Nab-paclitaxel In Breast Cancer Patimentioning

confidence: 99%

Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?

2016

View full text Add to dashboard Cite

Abstract:The therapeutic goals in metastatic breast cancer (MBC) remain palliative in nature, aimed at controlling symptoms, improving or maintaining quality of life and prolonging survival. The advent of new drugs and new formulations of standard agents has led to better outcomes in patients with advanced or metastatic disease. These developments have also allowed a tailored therapeutic approach, in which the molecular biology of the tumour, the treatment history, and patient attitudes are taken into account in the decision-making process. Targeting drug delivery to the tumour is a promising mean of increasing the therapeutic index of highly active agents such as the taxanes, and nanoparticle albuminbound paclitaxel (nab-paclitaxel), the first nanotechnology-based drug developed in cancer treatment, is one such advance. Data from randomized trials support the efficacy of singleagent nab-paclitaxel as first-line and further treatment lines in MBC at the registered 3-weekly schedule of 260 mg/m 2 , but emerging evidence suggests its activity as a weekly regimen or combined with other agents in various clinical scenarios. Thus, nab-paclitaxel seems to offer flexibility in terms of dosing schedules, allowing physicians to tailor the dose according to different clinical situations. This paper reviews the clinical trial background for nab-paclitaxel in MBC, focusing on specific 'difficult-to-treat' patient populations, such as taxane-pretreated or elderly women, as well as those with triple-negative, HER2-positive and poor-prognosticfactors disease. Moving beyond evidence-based information, 'real life' available experiences are also discussed with the aim of providing an update for daily clinical practice.

show abstract

“…An ErbB2 amplification occurs in about 15–20% of breast cancers [15,84,85]. Metastatic ErbB2-positive breast cancer correlates with increased aggressiveness, poor prognosis, and short overall survival time [86]. The overexpressed receptor represents a paradigm for oncoprotein addiction, and with that a valuable predictive biomarker and therapeutic target.…”

Section: Erbb Proteins and Oncogene Addictionmentioning

confidence: 99%

ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology

Jacobi

Seeboeck

Hofmann

et al. 2017

Cancers

View full text Add to dashboard Cite

ErbB family members represent important biomarkers and drug targets for modern precision therapy. They have gained considerable importance as paradigms for oncoprotein addiction and personalized medicine. This review summarizes the current understanding of ErbB proteins in cell signalling and cancer and describes the molecular rationale of prominent cases of ErbB oncoprotein addiction in different cancer types. In addition, we have highlighted experimental technologies for the development of innovative cancer cell models that accurately predicted clinical ErbB drug efficacies. In the future, such cancer models might facilitate the identification and validation of physiologically relevant novel forms of oncoprotein and non-oncoprotein addiction or synthetic lethality. The identification of genotype-drug response relationships will further advance personalized oncology and improve drug efficacy in the clinic. Finally, we review the most important drugs targeting ErbB family members that are under investigation in clinical trials or that made their way already into clinical routine. Taken together, the functional characterization of ErbB oncoproteins have significantly increased our knowledge on predictive biomarkers, oncoprotein addiction and patient stratification and treatment.

show abstract

HER2-positive metastatic breast cancer: A changing scenario

Cited by 28 publications

References 62 publications

Breast Cancer-Derived Extracellular Vesicles: Characterization and Contribution to the Metastatic Phenotype

Breast Cancer-Derived Extracellular Vesicles: Characterization and Contribution to the Metastatic Phenotype

Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?

ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology

Contact Info

Product

Resources

About